Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn's disease: a meta-analysis.

Binion DG, Louis E, Oldenburg B, Mulani P, Bensimon AG, Yang M, Chao J.

Can J Gastroenterol. 2011 Sep;25(9):492-6.

2.

Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial.

Louis E, Löfberg R, Reinisch W, Camez A, Yang M, Pollack PF, Chen N, Chao J, Mulani PM.

J Crohns Colitis. 2013 Feb;7(1):34-43. doi: 10.1016/j.crohns.2012.02.017. Epub 2012 Apr 4.

PMID:
22480772
3.

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.

Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J, Fry-Smith A, McCabe C, Meads C.

Health Technol Assess. 2011 Feb;15(6):1-244. doi: 10.3310/hta15060. Review.

4.

Health-Related Quality of Life Impairment and Indirect Cost of Crohn's Disease: A Self-Report Study in Poland.

Holko P, Kawalec P, Mossakowska M, Pilc A.

PLoS One. 2016 Dec 16;11(12):e0168586. doi: 10.1371/journal.pone.0168586. eCollection 2016.

5.
6.

Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study.

van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, de Jong DJ, Pierik M, van der Woude CJ, Romberg-Camps MJ, Clemens CH, Jansen JM, Mahmmod N, van de Meeberg PC, van der Meulen-de Jong AE, Ponsioen CY, Bolwerk CJ, Vermeijden JR, Siersema PD, van Oijen MG, Oldenburg B; COIN study group and the Dutch Initiative on Crohn and Colitis.

Gut. 2014 Jan;63(1):72-9. doi: 10.1136/gutjnl-2012-303376. Epub 2012 Nov 7.

PMID:
23135759
7.

The Value of Vedolizumab as Rescue Therapy in Moderate-Severe Crohn's Disease Patients with Adalimumab Non-response in the USA.

Erim DO, Mahendraratnam N, Okafor PN, Wheeler SB.

J Crohns Colitis. 2015 Aug;9(8):669-75. doi: 10.1093/ecco-jcc/jjv090. Epub 2015 May 18.

PMID:
25987351
8.

[The cost effectiveness of adalimumab in Crohn's disease (review of foreign pharmacoeconomic studies)].

Rudakova AV.

Eksp Klin Gastroenterol. 2011;(9):113-9. Review. Russian. No abstract available.

PMID:
22629787
9.

Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis.

Zhang W, Bansback N, Guh D, Li X, Nosyk B, Marra CA, Anis AH.

J Rheumatol. 2008 Sep;35(9):1729-36. Epub 2008 Aug 1.

PMID:
18688916
10.

Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease.

Blackhouse G, Assasi N, Xie F, Marshall J, Irvine EJ, Gaebel K, Campbell K, Hopkins R, O'Reilly D, Tarride JE, Goeree R.

J Crohns Colitis. 2012 Feb;6(1):77-85. doi: 10.1016/j.crohns.2011.07.007. Epub 2011 Sep 9.

PMID:
22261531
11.

The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis.

Kimball AB, Yu AP, Signorovitch J, Xie J, Tsaneva M, Gupta SR, Bao Y, Mulani PM.

J Am Acad Dermatol. 2012 Feb;66(2):e67-76. doi: 10.1016/j.jaad.2010.10.020. Epub 2011 May 25.

PMID:
21616560
12.

Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials.

Sandborn WJ, Colombel JF, Panés J, Castillo M, Robinson AM, Zhou Q, Yang M, Thakkar R.

J Crohns Colitis. 2013 Dec;7(12):958-67. doi: 10.1016/j.crohns.2013.02.016. Epub 2013 Mar 18.

PMID:
23517933
13.

Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease.

Reilly MC, Gerlier L, Brabant Y, Brown M.

Clin Ther. 2008 Feb;30(2):393-404. doi: 10.1016/j.clinthera.2008.02.016.

PMID:
18343277
14.

The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy.

Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, Wu E, Yu AP, Cardoso AT, Chao J, Mulani PM, Lomax KG, Kent JD.

Aliment Pharmacol Ther. 2010 Nov;32(10):1228-39. doi: 10.1111/j.1365-2036.2010.04466.x. Epub 2010 Sep 28.

15.

Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease.

Loftus EV Jr, Johnson SJ, Yu AP, Wu EQ, Chao J, Mulani PM.

Eur J Gastroenterol Hepatol. 2009 Nov;21(11):1302-9. doi: 10.1097/MEG.0b013e32832a8d71.

PMID:
19465858
16.

Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study.

Feagan BG, Reilly MC, Gerlier L, Brabant Y, Brown M, Schreiber S.

Aliment Pharmacol Ther. 2010 Jun;31(12):1276-85. doi: 10.1111/j.1365-2036.2010.04303.x. Epub 2010 Mar 18.

17.

Adalimumab induces deep remission in patients with Crohn's disease.

Colombel JF, Rutgeerts PJ, Sandborn WJ, Yang M, Camez A, Pollack PF, Thakkar RB, Robinson AM, Chen N, Mulani PM, Chao J.

Clin Gastroenterol Hepatol. 2014 Mar;12(3):414-22.e5. doi: 10.1016/j.cgh.2013.06.019. Epub 2013 Jul 12.

PMID:
23856361
18.

Implications of Infliximab Treatment Failure and Influence of Personalized Treatment on Patient-reported Health-related Quality of Life and Productivity Outcomes in Crohn's Disease.

Steenholdt C, Brynskov J, Thomsen OØ, Munck LK, Christensen LA, Pedersen G, Kjeldsen J, Ainsworth MA.

J Crohns Colitis. 2015 Nov;9(11):1032-42. doi: 10.1093/ecco-jcc/jjv139. Epub 2015 Aug 5.

PMID:
26245216
19.

Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.

Gordon M, Taylor K, Akobeng AK, Thomas AG.

Cochrane Database Syst Rev. 2014 Aug 1;(8):CD010233. doi: 10.1002/14651858.CD010233.pub2. Review.

PMID:
25081347
20.

Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis.

Maksymowych WP, Gooch KL, Wong RL, Kupper H, van der Heijde D.

J Rheumatol. 2010 Feb;37(2):385-92. doi: 10.3899/jrheum.090242. Epub 2009 Dec 1.

PMID:
19955052

Supplemental Content

Support Center